How to use Fam-trastuzumab deruxtecan-nxki

The patient starts taking Fam-trastuzumab deruxtecan-nxki and needs to be tested for relative gene mutations and tumor samples. Do not substitute trastuzumab or ado-trastuzumab emtansine for trastuzumab. Because trastuzumab is an injectable formulation, slow down or interrupt the infusion rate if the patient develops infusion-related symptoms. Trastuzumab can only be administered intravenously through an infusion set made of polyolefin or polybutadiene, administered over 90 minutes for the first infusion, or within 30 minutes if the previous infusion was well tolerated.

Trastuzumab may cause moderate emetogenicity in patients, including delayed nausea and/or vomiting. Take prophylactic antiemetic medications according to local agency guidelines for preventing chemotherapy-induced nausea and vomiting. For patients with breast cancer (MBC) and non-small cell lung cancer (NSCLC) the recommended dose of trastuzumab is 5.4mg/kg, intravenously infused once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. For patients with gastric cancer (MGC), the recommended dose of trastuzumab is 6.4 mg/kg as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

If a patient develops an adverse reaction while taking trastuzumab, it may be necessary to temporarily interrupt, reduce the dose, or discontinue treatment with trastuzumab. After a dose reduction, do not increase the dose of trastuzumab . If a scheduled dose is delayed or missed, administer the dose as soon as possible and do not wait until the next scheduled cycle. Adjust the dosing schedule to maintain an interval of 3 weeks between doses, and infuse according to the dose and rate tolerated by the patient in the most recent infusion. If a serious infusion reaction occurs, permanently discontinue trastuzumab.

If a serious infusion reaction occurs, permanently discontinue trastuzumab. For patients with breast cancer and non-small cell lung cancer, the first dose of trastuzumab is reduced to 4.4 mg/kg, and the second dose is reduced to 3.2 mg/kg. If further reduction is needed, treatment is stopped; for patients with gastric cancer, the first dose of trastuzumab is reduced to 5.4 mg/kg, and the second dose is reduced to 4.4 mg/kg. If further reduction is needed, treatment is stopped.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been marketed in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of trastuzumab Specifications may cost more than 10,000 yuan per box of 100 mg. The Hong Kong original versionDetrastuzumab Original drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. There is currently no generic version of Detrastuzumab on the market. For more specific prices and drug information, please consult the medical consultant of the drug.